This study evaluated the effect of eicosapentaenoic acid (EPA) on episodic migraine (EM) prevention in a 12-week randomized, double-blind, placebo-controlled trial involving 70 individuals with EM. Participants were randomly assigned to receive either 2 g of fish oil with 1.8 g of EPA daily or a placebo. The results showed that the EPA group significantly outperformed the placebo group in reducing monthly migraine days, days using acute headache medication, headache severity, disability, anxiety, depression, and quality of life. Notably, female participants particularly benefited from EPA supplementation. The study concluded that high-dose EPA has the potential to reduce migraine frequency and severity, improve psychological symptoms, and enhance overall quality of life in EM patients, with no significant adverse events observed. This suggests that EPA could be a promising prophylactic treatment for EM.This study evaluated the effect of eicosapentaenoic acid (EPA) on episodic migraine (EM) prevention in a 12-week randomized, double-blind, placebo-controlled trial involving 70 individuals with EM. Participants were randomly assigned to receive either 2 g of fish oil with 1.8 g of EPA daily or a placebo. The results showed that the EPA group significantly outperformed the placebo group in reducing monthly migraine days, days using acute headache medication, headache severity, disability, anxiety, depression, and quality of life. Notably, female participants particularly benefited from EPA supplementation. The study concluded that high-dose EPA has the potential to reduce migraine frequency and severity, improve psychological symptoms, and enhance overall quality of life in EM patients, with no significant adverse events observed. This suggests that EPA could be a promising prophylactic treatment for EM.